Detailed Information on Publication Record
2021
Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
HYZA, M., P. SILHAN, E. CESKOVA, T. SKRONT, I. KACIROVA et. al.Basic information
Original name
Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
Authors
HYZA, M., P. SILHAN, E. CESKOVA, T. SKRONT, I. KACIROVA, R. URINOVSKA and M. GRUNDMANN
Edition
Neuropsychiatric Disease and Treatment, New Zealand, Dove Medical Press, 2021, 1176-6328
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.154 in 2013
UT WoS
000641063300001
Keywords in English
therapeutic drug monitoring; antipsychotics; psychotic disorders; schizophrenia
Tags
Změněno: 7/12/2021 13:00, Bc. Hana Vladíková, BBA
Abstract
V originále
Purpose: Antipsychotic efficacy in schizophrenia depends on its availability in the body. Although therapeutic outcomes remain still far from satisfactory, therapeutic drug monitoring not a common part of clinical practice during treatment with long-acting injectable antipsychotics (LAI AP). The real effectiveness of LAI AP is thus uncertain. Patients and Methods: We made a retrospective evaluation of plasma levels of LAI AP. Collection of blood samples was performed just before the drug application and one week later. Forty patients with a stabilized clinical condition and steady-state plasma levels were included. Results: In the observed cohort of patients, flupentixol decanoate (n = 23) was the most often used drug, followed by fluphenazine decanoate (n = 7), haloperidol decanoate (n = 5), paliperidone palmitate (n = 3), and risperidone microspheres (n = 2). Just 5 of 40 patients were treated with a monotherapy. In the period before the application, 60% of the patients did not reach the therapeutic reference range (TRR) and 20% of the patients had an undetectable plasma level. At the time of collection of the second blood samples performed after 7 days, 24% of the patients were under the TRR. Conclusion: We have found a surprisingly high incidence of plasma levels under the TRR patients treated with LAI AP. Notwithstanding individual variability in pharmacokinetics, seems that LAI AP may be underdosed in usual clinical practice.
Links
90128, large research infrastructures |
|